Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | CPA3 | P15088 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265135 | 1.00 | CYP1A2 (0.61) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| SCHEMBL65930 | 1.00 | CYP1A2 (0.61) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| SCHEMBL27514358 | 0.98 | CYP1A2 (0.59) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| Water SCHEMBL10936876 | 0.98 | CYP1A2 (0.59) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| SCHEMBL11237591 | 0.91 | TBXAS1 (0.59) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| Tert-Butylamine SCHEMBL1883188 | 0.90 | ALPI (0.53) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| Tert-Butylamine SCHEMBL1880992 | 0.90 | ALPI (0.53) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| Tert-Butylamine SCHEMBL1880991 | 0.90 | ALPI (0.53) | CYP1A2TBXAS1HPGDCYP3A4TSHR | |
| SCHEMBL7507834 | 0.88 | MME (0.63) | CPA1 | |
| SCHEMBL16948243 | 0.88 | MME (0.63) | CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101912382-B | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPE SPA | 2012-11-21 | — | — | CN | claimed |
| CN-101912382-A | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPE SPA | 2010-12-15 | — | — | CN | claimed |
| CN-1934077-B | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPE PHA R MA SPA RES & MFG | 2010-09-29 | — | — | CN | claimed |
| CN-122059780-A | Asymmetric synthesis method of alpha-chiral ester compound | 内蒙古大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-115043721-B | Preparation method of alpha-substituted chiral carboxylic acid compound | 山东师范大学 | 2024-03-26 | — | — | CN | disclosed |
| US-20240024410-A1 | THREE-DIMENTIONAL SURFACE FOR PROTEIN AND SMALL MOLECULE MICROARRAYS | THE JOHNS HOPKINS UNIVERSITY | 2024-01-25 | — | — | US | disclosed |
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022224035-A2 | ANTI-GM1 ANTIBODY BINDING COMPOUNDS | POLYNEURON PHARMACEUTICALS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| CN-115043721-A | Preparation method of alpha-substituted chiral carboxylic acid compound | 山东师范大学 | 2022-09-13 | — | — | CN | disclosed |
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2021-10-21 | — | — | US | disclosed |
| US-5302528-A | Hydrolysis of a racemic ester mixture to the stereospecific alpha-aryl or -aryloxyalkanoic acid | Ministero Dell `Universita` e Della Ricerca Scientifica e Technologica (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0229614-B1 | PROCESS FOR THE SELECTIVE REGENERATION OF MEDIATORS AND CATALYST THEREFOR | BASF Aktiengesellschaft (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0510712-A2 | Process for the separation of the optical isomers of alpha-substituted carboxylic acids | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1992-10-28 | — | — | EP | disclosed |
| CN-1055181-A | SELECTIVE ADENOSINE RECEPTOR AGENTS | MERRELL DOW PHARMA (US) | 1991-10-09 | — | — | CN | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5047534-A | Xanthine derivatives; hyupotensive agents, cardiotonic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-10 | — | — | US | disclosed |
| US-4837189-A | Surfactant modified metal catalysts | BASF AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| US-4749670-A | Selective regeneration of mediators in the presence of a catalyst and surfactant | BASF AKTIENGESELLSCHAFT (DE) | 1988-06-07 | — | — | US | disclosed |
| EP-0229614-A2 | Process for the selective regeneration of mediators and catalyst therefor | BASF Aktiengesellschaft (DE) | 1987-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, TIMP3 | CYP1A2 1427/4885TBXAS1 1150/4885HPGD 197/4885 |
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | SLC2A1, SLC2A4, SLC2A2 | CYP1A2 3807/4885TBXAS1 1014/4885HPGD 3458/4885 |
| US-20240024410-A1 | THREE-DIMENTIONAL SURFACE FOR PROTEIN AND SMALL MOLECULE MICROARRAYS | MRPS23, CD2BP2, MRPL21 | CYP1A2 4720/4885TBXAS1 2417/4885HPGD 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.